News

Researchers call for more pragmatic clinical trials in MS

Few multiple sclerosis (MS) clinical trials have used a so-called pragmatic design, which evaluates the effectiveness of interventions in real-life routine practice, a study has found. Because such trials are better able to emulate conditions in real-world clinical practice and provide solid and more actionable evidence to inform treatment…

Aptar to operate, develop Biogen’s lifestyle support apps for MS

Under a new agreement, Biogen is transferring ownership of certain digital health solutions — including two existing mobile applications, or apps, offering lifestyle support to people with multiple sclerosis (MS) — to Aptar Digital Health. The collaboration calls for Aptar, part of AptarGroup, to handle product design…

Sharp lymphocyte drop seen quickly in SPMS patients on Mayzent

Some people with secondary progressive multiple sclerosis (SPMS) using Mayzent (siponimod) show a severe drop in their number of lymphocytes, a condition known as lymphopenia, shortly after starting treatment, a report on its real-world use in the U.K. found. Lymphocytes are white blood cells that help the immune…

Helius to showcase PoNS device at physical therapy meeting Feb. 15-17

Helius Medical Technologies will be showcasing its now-accredited PoNS device — designed to improve walking ability in people with multiple sclerosis (MS) — at this year’s American Physical Therapy Association (APTA) Combined Sections Meeting (CMS), slated for Feb. 15-17. The annual meeting, which will feature educational sessions, exhibits,…

Non-invasive MEG scan can predict cognitive therapy outcomes in MS

A non-invasive scan that measures network activity across the brain was able to predict the outcomes of behavioral therapies designed to improve cognitive function in people with multiple sclerosis (MS), a study demonstrates. Brain network function, as assessed by the test, called magnetoencephalography (MEG), “could play an important role…

Real-world data can be used to compare efficacy of MS treatments

Real-world data collected from a registry can be used to reliably compare the effectiveness of different multiple sclerosis (MS) treatments, so long as appropriate methodologies are employed to account for the messiness — what researchers call confounding bias — of real-world data, according to a new study. While registries…

Fatigue predicts worse health-related quality of life in RRMS

Fatigue is a significant predictor of worse health-related quality of life in adults with relapsing-remitting multiple sclerosis (RRMS), a study reports. High levels of fatigue were significantly linked with worse physical and mental health, including cognitive impairments, depression, and anxiety. The findings suggest…

Tysabri biosimilar Tyruko now available in Germany for RRMS

Tyruko (natalizumab), the first biosimilar of Tysabri, is now available in Germany for adults with highly active relapsing-remitting multiple sclerosis (RRMS). As a biosimilar, Tyruko has the same safety and efficacy profile, mechanism of action, and pharmacological properties as Tysabri. Biosimilars are typically sold at lower prices than their reference medication,…

Myelin repair early in MS may protect against disability worsening

People in the early stages of multiple sclerosis (MS) who have more spontaneous myelin repair in the cortex — the outermost layer of the brain that’s critical for higher cognitive abilities — are less likely to experience worsening disability, a new analysis suggests. These findings have important implications for…